Key to biosim­i­lar com­pe­ti­tion will come from in­ter­change­abil­i­ty, FDA of­fi­cials say

With the growth in bi­o­log­ics spend­ing, the biosim­i­lar mar­ket is go­ing to have to find new ways to keep up.

One av­enue may open up with new in­ter­change­able biosim­i­lars that can be sub­sti­tut­ed with­out a doc­tor’s note, and which could help bring costs down for some prici­er, pa­tient-ad­min­is­tered ther­a­pies. FDA of­fi­cials dis­cussed key flex­i­bil­i­ties that they can make around the de­vel­op­ment of in­ter­change­able biosim­i­lars at an As­so­ci­a­tion for Ac­ces­si­ble Med­i­cines’ in­dus­try con­fer­ence yes­ter­day in Bethes­da, Md.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.